

11th International Meeting on Metabotropic Glutamate Receptors: From the bench to the clinic

Palazzo Polifunzionale Letojanni (Me)

October 1st -3rd, 2024

Tuesday - October 1, 2024 Morning session AM

Neurodevelopment and developmental disorders

Chair: Maria Vincenza Catania (Italy)

8.00 – 8.25 **Role of mGlu7 in neurodevelopmental disorders** Colleen Niswender (USA)

8.25 – 8.50 **DYSREGULATED NEURONAL PATHWAYS IN CDKL5-DEFICIENCY DISORDER CONVERGE ON mGLU5 RECEPTORS** Maurizio Giustetto (Italy)

8.50 – 9.15 **Behavioral and molecular phenotypes of a non-human primate model for fragile X syndrome** Atzu Aiba (Japan)

9.15 – 9.40 **Roles of mGluR1 in activity-dependent synapse elimination during postnatal development** Masanobu Kano (Japan)

9.40 – 10.05 **Loss-of-Function of mGluR5 Disrupts the Development of Synaptic Excitatory Transmission in the Sound Localization Circuit of the Mammalian Brainstem** Yong Lu (USA)

10.05 – 10.25 break

Autoimmune disorders, multiple sclerosis, NMOSD

Chair: Giuseppe Battaglia (Italy)

10.25 – 10.50 **Role of glutamate and glutamate receptors in the inflammatory synaptopathy of MS** Diego Centonze (Italy)

10.50 – 11.15 **Pathophysiology and novel molecular targets of NMOSD** Claudio Gasperini (Italy)

11.15 – 11.40 **Antibodies against metabotropic Glutamate receptor in neurological disorders** Matteo Gastaldi (Italy)

11.40 – 12.05 **In vitro and in vivo effects of encephalitis patient-derived mGluR autoantibodies** Jakob Kreye (Germany)

12.05 – 12.30 **Unlocking the role of cellular prion protein involvement in multiple sclerosis: is there a role for metabotropic glutamate receptors?**

Francesca Fallarino (Italy)

ORGANIZING SECRETARIAT

CENTRO ORGANIZZAZIONE CONGRESSI
Via San Pancrazio 4 - 98039 Taormina (ME) Italy

and PROVIDER ECM 2263

info@centrocongressi.biz

Tuesday - October 1, 2024 Afternoon session PM

Parkinson's disease and other neurodegenerative disorders

Chair: Angela Cenci (Sweden) - Yoland Smith (USA)

4.00 – 4.25 **Parkinson's disease a look to the future** Fabrizio Stocchi (Italy)

4.25 – 4.50 **Glutamatergic neurotransmission in Parkinson's disease and its role in the control of motor and non-motor symptoms** Javier Pagonabarraga (Spain)

4.50- 5.15 **mGlu3 receptors and Parkinson's disease** Giuseppe Battaglia (Italy)

5.15 – 5.40 **Metabotropic glutamate receptors in mouse and monkey models of Parkinson's disease: neuroprotection, antiparkinsonian and anti-dyskinetic activities** Therese Di Paolo Chenevert (Canada)

5.40 – 6.05 **Renewed interest in mGlu4 as a target for the treatment of Parkinson's disease: development of a novel, potent, and selective mGlu4 PAM (AP-472)** Annie Blobaum (USA) - Brian Laden (USA)

2

Wednesday- October 2, 2024 Morning session AM

**Disorders of negative affect
(depression, anxiety, stress-related disorders)**

Chair: Francesco Ferraguti (Austria) - Stefania Maccari (France)

8.00 – 8.25 **The Complexity and Heterogeneity of Depressive Syndrome and the Difficulty of Testing the Efficacy of Specific Medications for Specific Subtypes** Andrea Fagiolini (Italy)

8.25 – 8.50 **The antidepressant activity of hallucinogenic substances is enhanced by group II mGlu receptor antagonists** Andrzej Pilc (Poland)

8.50 – 9.15 **Neural mechanisms of anxiolysis of mGlu5 receptor antagonists** Francesco Ferraguti (Austria)



9.15 – 9.40 **Interplay between the mGluR2 signalling and ketamine's rapid antidepressant actions: Exploring the possible role of NMDAR activation** Panos Zanos (Cyprus)

9.40 – 10.05 **Exploring the role of cinnabarinic acid in anhedonia** Francesco Fazio (USA)

10.05 – 10.30 break

Psychotic disorders

Chair: Jeffry Conn (USA) – Francesco Matrisciano (USA)

10.30 – 10.55 **Schizophrenia: Pathophysiology and Novel Mechanism Action Treatments** Christoph U Correll (Germany/USA)

10.55 -11.20 **Therapeutic potential of mGlu3 for the treatment of schizophrenia** Shalini Dogra (USA)

11.20 – 11.45 **Potential role for mGlu2/3 receptors in treatment-resistant schizophrenia** Francesco Matrisciano (USA)

11.45 – 12.10 **Metamodulation of mGluRs: the role of serotonin** Anna Pittaluga (Italy)

Wednesday - October 2, 2024 Afternoon session PM

Drug addiction

Chair: Joel Bockaert (France)

3.30 – 3.55 **Mechanisms of mGlu1 regulation of cortical inhibition and cognitive function: Implications in adolescent cocaine exposure** Deborah Luessen (USA)

3.55 – 4.20 **The Dorsal Raphe→Central Amygdala glutamatergic pathway is critical to methamphetamine relapse after contingency management** Daniele Caprioli (Italy)

4.20 – 4.45 **Parvalbumin interneuron mGlu5 receptors govern sex differences in prefrontal cortical physiology and binge drinking** Max Joffe (USA)

4.45 – 5.10 **The endocannabinoid system in cocaine dependence and their relation to mGluR5 density in the human brain** Sara Liane Kroll (Switzerland)

5.10 – 5.35 **Cortical mGlu2/3 receptors and methamphetamine-induced behavioral deficits** Marek Schwendt (USA)

5.35 – 6.00 **Role of accumbens medium spiny neurons subtypes in reinstatement to ketamine cues** Mohamed Kabbaj (USA)

ORGANIZING SECRETARIAT

CENTRO ORGANIZZAZIONE CONGRESSI
Via San Pancrazio 4 - 98039 Taormina (ME) Italy

and PROVIDER ECM 2263

info@centrocongressi.biz



Thursday- October 3, 2024 Morning session AM

Chronic pain

Chair: Tom Salt (UK)

9.00 – 9.25 **Objective in clinical trials of pain treatments** Smriti Iyengar (USA)

9.25 – 9.50 **Pain neuromodulation by the metabotropic glutamate receptor mGlu4: from the periphery to the brain** Cyril Goudet (France)

9.50 – 10.15 **mGlu and neuroimmune signaling in the amygdala in pain modulation** Volker Neugebauer (USA)

10.15 – 10.40 break

10.40 – 11.05 **Neuroinflammation and central sensitization in acute and chronic pain: from the bench to the clinical practice** Salvatore Cuzzocrea (Italy)

11.05 – 11.30 **mGluRs in cortical synaptic plasticity or mGluRs in pain/emotion** Min Zhuo (Canada)

4

Thursday - October 3, 2024 Afternoon session PM

Stroke and excitotoxicity

Chair: Agata Copani (Italy), Valeria Bruno (Italy)

3.30 – 3.55 **Inhibition of mGluR5 restores lost sensorimotor function after stroke – from bench to bedside** Tadeusz Wieloch (Sweden)

3.55 – 4.20 **Inhibition of mGluR5 restores brain functional connectivity after stroke in mice.** Adam Bauer (USA)

4.20 – 4.45 **Cannabinoids and cannabinoid receptors in models of stroke** Domenico Pellegrini Giampietro (Italy)

Epilepsy

4.45 – 5.10 **Development of mGlu ligand** Robert Lutjens (Switzerland)

5.10 – 5.35 **Decoding early-onset epilepsy and targeted disease management: the importance of genetic testing** Pasquale Striano (Italy)

ORGANIZING SECRETARIAT

CENTRO ORGANIZZAZIONE CONGRESSI
Via San Pancrazio 4 - 98039 Taormina (ME) Italy

and PROVIDER ECM 2263

info@centrocongressi.biz



5.35 – 6.00 **NGS analysis of glutamatergic systems in schizophrenia and epilepsy** Andrius Baskys (USA)

6.00 – 6.25 **Complimentary Regulation of Metabotropic mGluR1 α and Ionotropic AMPA Receptors Following Chronic Anticonvulsant Treatment During Postnatal Development in Presence and Absence of Seizures** Linda Friedman (USA)

